Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and tolerability of vorinostat in combination with
decitabine as well as the in vivo molecular and biological effects of vorinostat in patients
with refractory or relapsed Acute Myelogenous Leukemia (AML) and intermediate or high risk as
defined by International Prognostic Scoring System (IPSS) Myelodysplastic Syndrome (MDS).
Participants with Acute Myelogenous Leukemia or Myelodysplastic Syndrome are eligible.